- Home
- CLLS
CLLS
Cellectis S.A.
as 06-27-2025 11:30am EST
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
| Founded: | 1999 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 143.4M | IPO Year: | 2007 |
| Target Price: | $4.00 | AVG Volume (30 days): | 50.1K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.10 - $2.43 | Next Earning Date: | 08-05-2025 |
| Revenue: | $54,747,000 | Revenue Growth: | 351.26% |
| Revenue Growth (this year): | 48.52% | Revenue Growth (next year): | 5.17% |
Latest Cellectis S.A. News
CLLS Breaking Stock News: Dive into CLLS Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025
MT Newswires
5 days ago
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
Simply Wall St.
6 days ago
European Penny Stocks To Watch In June 2025
MT Newswires
7 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
GlobeNewswire
a month ago
Monthly information on share capital and company voting rights
Simply Wall St.
a month ago
European Penny Stocks To Consider In May 2025
GlobeNewswire
a month ago
Cellectis’ Annual Shareholders General Meeting to be Held on June 26, 2025
GlobeNewswire
2 months ago
Cellectis Reports Financial Results for the First Quarter 2025
Compare CLLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLLS Cellectis S.A. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.